Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study - 2026
Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study
Philips, Jean-Christophe ; Université de Liège - ULiège > Département des sciences de la santé publique
Feodor, Toni
Language :
English
Title :
Effectiveness of Conservative Treatment on Chronic Venous Disease Symptoms and Quality of Life in Patients with Type 2 Diabetes: Results from a Subanalysis of the VEIN STEP Observational Study
Davies AH. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther. 2019;36(Suppl S1):5–13. doi:10.1007/s12325-019-0881-7
Lurie F, Passman M, Meisner M, et al.The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–52.2. doi:10.1016/j.jvsv.2019.12.075
Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976. doi:10.1097/SLA.0000000000004631
Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham study. Am J Prev Med. 1988;4(2):96–101. doi:10.1016/S0749-3797(18)31203-0
Criqui MH, Denenberg JO, Bergan J, Langer RD, Fronek A. Risk factors for chronic venous disease: the San Diego population study. J Vasc Surg. 2007;46(2):331–337. doi:10.1016/j.jvs.2007.03.052
He J, Ma F, Yao J, et al.Dietary effects on chronic venous disease. Ann Vasc Surg. 2023;88:257–267. doi:10.1016/j.avsg.2022.06.015
Hariharan R, Odjidja EN, Scott D, et al.The dietary inflammatory index, obesity, type 2 diabetes, and cardiovascular risk factors and diseases. Obes Rev. 2022;23(1):e13349. doi:10.1111/obr.13349
International Diabetes Federation. Diabetes Atlas. Available from: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/. Accessed July10, 2025.
Kovács N, Shahin B, Andrade CAS, Mahrouseh N, Varga O. Lifestyle and metabolic risk factors, and diabetes mellitus prevalence in European countries from three waves of the European health interview survey. Sci Rep. 2024;14(1):11623. doi:10.1038/s41598-024-62122-y
Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: insights from animal models of venous hypertension. J Vasc Surg. 2008;47(1):183–192. doi:10.1016/j.jvs.2007.09.028
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–1346. doi:10.1016/S0140-6736(05)61032-X
Gastaldi G, Pannier F, Roztočil K, et al.Chronic venous disease and diabetic microangiopathy: pathophysiology and commonalities. Int Angiol. 2021;40(6):457–469. doi:10.23736/S0392-9590.21.04664-2
Marston WA, Carlin RE, Passman MA, Farber MA, Keagy BA. Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J Vasc Surg. J Vascu Surg. 1999;30(3):491. doi:10.1016/s0741-5214(99)70076-5
Lionis C, Erevnidou K, Antonakis N, Argyriadou S, Vlachonikolis I, Katsamouris A. Chronic venous insufficiency. A common health problem in general practice in Greece. Int Angiol. 2002;21(1):86–92.
Mani R, Yarde S, Edmonds M. Prevalence of deep venous incompetence and microvascular abnormalities in patients with diabetes mellitus. Int J Low Extrem Wounds. 2011;10(2):75–79. doi:10.1177/1534734611409372
Jarošíková R, Roztočil K, Husáková J, et al.Chronic venous disease and its intersections with diabetes mellitus. Physiol Res. 2023;72(3):280–286. doi:10.33549/physiolres.935033
Mezalek ZT, Feodor T, Chernukha L, et al.VEIN STEP: a prospective, observational, international study to assess effectiveness of conservative treatments in chronic venous disease. Adv Ther. 2023;40(11):5016–5036. doi:10.1007/s12325-023-02643-6
Launois R, Le Moine JG, Lozano FS, Mansilha A. Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure. Qual Life Res. 2012;21(6):1051–1058. doi:10.1007/s11136-011-0008-3
Le Moine J-G, Fiestas-Navarrete L, Katumba K, Launois R. Psychometric validation of the 14 items chronic venous insufficiency quality of life questionnaire (CIVIQ-14): confirmatory factor analysis. Eur J Vasc Endovasc Surg. 2016;51(2):268–274. doi:10.1016/j.ejvs.2015.08.020
Radak DJ, Vlajinac HD, Marinković JM, Maksimović MŽ, Maksimović ŽV. Quality of life in chronic venous disease patients measured by short chronic venous disease quality of life questionnaire (CIVIQ–14) in Serbia. J Vasc Surg. 2013;58(4):1006–1013. doi:10.1016/j.jvs.2011.08.003
American Venous Forum Ad Hoc Outcomes Working Group, Vasquez MA, Rabe E, McLafferty RB, et al.Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American venous forum ad hoc outcomes working group. J Vasc Surg. 2010;52(5):1387–1396. doi:10.1016/j.jvs.2010.06.161
Saeedi P, Petersohn I, Salpea P, et al.IDF diabetes atlas committee. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results From the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Res Clin Pract. 2019;157:107843.
Bozkurt AK, VAN Rijn MJ, Bouskela E, et al.Enhancing identification and treatment of patients with concomitant chronic venous insufficiency and diabetes mellitus. A modified Delphi study from the CODAC (ChrOnic venous disease and diabetes advisory council) group. Int Angiol. 2023;42(5):427–435. doi:10.23736/S0392-9590.23.05061-7
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530. doi:10.1016/S0140-6736(16)00618-8
Galicia-Garcia U, Benito-Vicente A, Jebari S, et al.Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. doi:10.3390/ijms21176275
Fejfarová V, Roztočil K, Svědínková A, et al.The relationship between chronic venous insufficiency and diabetes mellitus. Int Angiol. 2017;36(1):90–91. doi:10.23736/S0392-9590.16.03736-6
Shlyakova AA, Strongin LG, Kudykin MN, К.g K. Clinical and pathogenetic features of lesions of the lower extremities in patients with type 2 diabetes mellitus and chronic venous insufficiency. Diabetes mellitus. 2016;19(3):212–220.
Rajendran P, Rengarajan T, Thangavel J, et al.The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–1069. doi:10.7150/ijbs.7502
Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1669. doi:10.3390/ijms19061669
Charlton A, Garzarella J, Jandeleit-Dahm KAM, Jha JC. Oxidative stress and inflammation in renal and cardiovascular complications of diabetes. Biology. 2020;10(1):18. doi:10.3390/biology10010018
Zhong J, Chen J, Zhao Z-G, et al.Diabetes mellitus is associated with early chronic venous disorder of the lower extremities in Chinese patients with cardiometabolic risk factors. Diabetes Metab Res Rev. 2014;30(6):505–512. doi:10.1002/dmrr.2551
Rosas-Saucedo J, Lukanova D, Glauser F, et al.Treatment patterns for chronic venous disease and diabetes mellitus: lessons from an international market-research survey. Diabetes Manag. 2021;S1:1–10.
Agus GB, Mattana P, Monitor CF. 2010: italian epidemiological survey on chronic venous diseases. Acta Phlebologica. 2012;13(1):9–17.
Singh TP, Velu RB, Quigley F, Golledge J. Association of chronic venous disease with major adverse cardiovascular events. J Vasc Surg Venous Lymphat Disord. 2022;10(3):683–688. doi:10.1016/j.jvsv.2021.08.021
Deng L, Du C, Song P, et al.The role of oxidative stress and antioxidants in diabetic wound healing. Oxid Med Cell Longev. 2021;2021(1):8852759. doi:10.1155/2021/8852759
Perrin M, Eklof B, VAN Rij A, et al.Venous symptoms: the sym vein consensus statement developed under the auspices of the european venous forum. Int Angiol. 2016;35(4):374–398.
Blättler W, Mendoza E, Zollmann C, Bendix J, Amsler F. Homeostatic feelings–a novel explanation of vein symptoms derived from an experimental patient study. Vasa. 2019;48(6):492–501. doi:10.1024/0301-1526/a000807
Ulloa JH, Lurie F, Santiago FR, et al.Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease. Int Angiol. 2023;42(6):465–476. doi:10.23736/S0392-9590.23.05108-8
Santiago F. Quality of life in chronic venous disease: bridging the gap between patients and physicians. Clin Drug Investig. 2023;43(Suppl S1):3–8. doi:10.1007/s40261-023-01264-9
Rodríguez‐Almagro J, García‐Manzanares Á, Lucendo AJ, Hernández‐Martínez A. Health-related quality of life in diabetes mellitus and its social, demographic and clinical determinants: a nationwide cross-sectional survey. J Clin Nurs. 2018;27(21–22):4212–4223. doi:10.1111/jocn.14624
Nicolaides A, Kakkos S, Baekgaard N, et al.Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181–254. doi:10.23736/S0392-9590.18.03999-8
Huwait E, Mobashir M. Potential and therapeutic roles of diosmin in human diseases. Biomedicines. 2022;10(5):1076. doi:10.3390/biomedicines10051076
Testa R, Bonfigli AR, Genovese S, de Nigris V, Ceriello A. The possible role of flavonoids in the prevention of diabetic complications. Nutrients. 2016;8(5):310.
Das Graças C de Souza M, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694–702. doi:10.1016/j.ejvs.2018.02.009
Ulloa JH. Micronized purified flavonoid fraction (MPFF) for patients suffering from chronic venous disease: a review of new evidence. Adv Ther. 2019;36(Suppl S1):20–25. doi:10.1007/s12325-019-0884-4
Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143–154. doi:10.23736/S0392-9590.18.03975-5
